摘要
抗CD20人鼠嵌合型单克隆抗体利妥昔单抗可通过多种机制杀伤B细胞,目前广泛应用于治疗CD20阳性淋巴瘤以及某些免疫相关性疾病,如免疫性血小板减少性紫癜、自身免疫性溶血性贫血、Evans综合征、移植后淋巴增殖性疾病和系统性红斑狼疮等。本文综述利妥昔单抗在儿童血液病中的临床应用。
Rituximab is a chimeric mouse-human monoclonal antibody against the CD 20 antigen,which can kill the B cell.Rituximab is widely used in patients with CD20 positive lymphoma and some other immune related diseases,such as immune thrombocytopenic purpura,autoimmune hemolytic anemia,Evans syndrome,post transplant lymphoproliferative disease and systemic lupus erythematosus.This review summarizes the research progress of rituximab in the treatment of children with hematological disease.
出处
《世界临床药物》
CAS
2013年第3期144-147,共4页
World Clinical Drug
关键词
利妥昔单抗
儿童
血液病
rituximab
children
hematological disease
